Shearer Gregory C, Couser William G, Kaysen George A
Department of Veterans Affairs Northern California Health Care System, Mather, California, USA.
Kidney Int. 2004 Jan;65(1):228-37. doi: 10.1111/j.1523-1755.2004.00373.x.
Binding of very low-density lipoprotein (VLDL) isolated from serum of nephrotic rats VLDL to endothelial cells is defective. This defect is conferred on normal VLDL by prior incubation with high-density lipoprotein (HDL) from nephrotic, but not control rats. It is not known whether the defect is present in nascent VLDL (nVLDL) or is acquired after secretion. We test the hypothesis that VLDL is normal at the time of secretion from the liver and the defect in binding to endothelium is conferred following secretion through interaction with HDL.
nVLDL was synthesized by and collected from isolated perfused livers from either control or nephrotic rats. nVLDL was labeled with 3H-oleate to measure binding and 35S methionine to evaluate apolipoprotein exchange and composition. To test whether HDL conferred a binding defect, nVLDL was incubated with HDL obtained either from control or nephrotic rats prior to measurement of binding. To distinguish the effects of proteinuria from reduced albumin concentration we additionally incubated nVLDL with HDL obtained from rats with hereditary analbuminemia. Both HDL and VLDL were reisolated by centrifugation prior to subsequent binding and lipolysis determination. Exchange of 35S-labeled apolipoprotein E (apoE) among the subsequent VLDL and HDL fractions was determined. To determine the effect of HDL on lipolysis, HDL-treated VLDL was exposed to lipoprotein lipase-coated 96-well plates and 3H-oleate release measured. To establish whether differences in apoE content could explain the differences in binding and lipolysis, apoE was restored to nephrotic VLDL and lipolysis and binding were subsequently measured.
Binding of nephrotic nVLDL was greater than control nVLDL (0.58 +/- 0.13 vs. 0.75 +/- 0.07 ng protein bound/mg cell protein) (P= 0.04, N= 6). Lipolysis was similarly elevated (0.091 +/- 0.010 vs 0.064 +/- 0.002 nmol NEFA released/well/hour) (P < 0.05). Prior incubation with nephrotic HDL reduced binding of nVLDL obtained from either nephrotic or control livers (P= 0.02, N= 6). Treatment with nephrotic (vs. control) HDL reduced both binding (control nVLDL + control HDL, 0.64 +/- 0.02; control + nephrotic, 0.43 +/- 0.06; nephrotic + control, 0.69 +/- 0.05; and nephrotic + nephrotic, 0.62 +/- 0.04 mg VLDL protein/mg cell protein) and lipolysis (control nVLDL + control HDL, 0.053 +/- 0.004; control + nephrotic, 0.038 +/- 0.004; nephrotic + control, 0.069 +/- 0.004; and nephrotic + nephrotic, 0.062 +/- 0.004 nmol NEFA/well/hour) (P < 0.05 vs. nVLDL + control HDL) of nVLDL from either source. The apoE content of nVLDL coincubated with control HDL or analbuminemic HDL was increased compared nVLDL incubated with either no HDL or nephrotic HDL (P < 0.05). Similarly, the apoE/apoA-I ratio was reduced in HDL from nephrotic rats but not in HDL from controls (P < 0.05). Reintroduction of apoE to nephrotic VLDL resulted in increased binding.
Unlike circulating VLDL, binding of nVLDL from isolated livers from nephrotic rats to endothelial cells is greater and its lipolysis is increased compared to control nVLDL. Decreased binding and lipolysis is conferred following incubation with HDL isolated from control, but not nephrotic rats and binding can be restored by reintroduction of apoE. Thus both defects are conferred on VLDL by exposure to HDL obtained from nephrotic animals, possibly a consequence of a failure of nephrotic HDL to enrich VLDL with apoE during clearance.
从肾病大鼠血清中分离出的极低密度脂蛋白(VLDL)与内皮细胞的结合存在缺陷。通过与肾病大鼠而非对照大鼠的高密度脂蛋白(HDL)预先孵育,这种缺陷会赋予正常VLDL。目前尚不清楚该缺陷是存在于新生VLDL(nVLDL)中还是在分泌后获得。我们检验了以下假设:VLDL在从肝脏分泌时是正常的,与内皮细胞结合的缺陷是在分泌后通过与HDL相互作用而产生的。
nVLDL由对照或肾病大鼠的离体灌注肝脏合成并收集。nVLDL用3H - 油酸标记以测量结合情况,用35S - 蛋氨酸标记以评估载脂蛋白交换和组成。为了测试HDL是否会导致结合缺陷,在测量结合之前,将nVLDL与从对照或肾病大鼠获得的HDL孵育。为了区分蛋白尿与白蛋白浓度降低的影响,我们还将nVLDL与从遗传性无白蛋白血症大鼠获得的HDL孵育。在随后进行结合和脂解测定之前,通过离心重新分离HDL和VLDL。测定随后的VLDL和HDL组分之间35S标记的载脂蛋白E(apoE)的交换情况。为了确定HDL对脂解的影响,将经HDL处理的VLDL暴露于包被有脂蛋白脂肪酶的96孔板中,并测量3H - 油酸的释放。为了确定apoE含量的差异是否可以解释结合和脂解的差异,将apoE恢复到肾病VLDL中,随后测量脂解和结合情况。
肾病nVLDL的结合大于对照nVLDL(0.58±0.13对0.75±0.07 ng结合蛋白/mg细胞蛋白)(P = 0.04,N = 6)。脂解同样升高(0.091±0.010对0.064±0.002 nmol游离脂肪酸释放/孔/小时)(P < 0.05)。预先与肾病HDL孵育会降低从肾病或对照肝脏获得的nVLDL的结合(P = 0.02,N = 6)。用肾病(与对照相比)HDL处理会降低来自任何一种来源的nVLDL的结合(对照nVLDL +对照HDL,0.64±0.02;对照 +肾病,0.43±0.06;肾病 +对照,0.69±0.05;肾病 +肾病,0.62±0.04 mg VLDL蛋白/mg细胞蛋白)和脂解(对照nVLDL +对照HDL,0.053±0.004;对照 +肾病,0.038±0.004;肾病 +对照,0.069±0.004;肾病 +肾病,0.062±0.004 nmol游离脂肪酸/孔/小时)(与nVLDL +对照HDL相比,P < 0.05)。与对照HDL或无白蛋白血症HDL共同孵育的nVLDL的apoE含量相比未与HDL或肾病HDL孵育的nVLDL有所增加(P < 0.05)。同样,肾病大鼠HDL中的apoE/apoA - I比值降低,但对照大鼠HDL中未降低(P < 0.05)。将apoE重新引入肾病VLDL会导致结合增加。
与循环中的VLDL不同,来自肾病大鼠离体肝脏的nVLDL与内皮细胞的结合更强,其脂解作用相比于对照nVLDL也有所增加。与从对照而非肾病大鼠分离的HDL孵育后,结合和脂解作用降低,并且通过重新引入apoE可以恢复结合。因此,这两种缺陷都是由于暴露于从肾病动物获得的HDL而赋予VLDL的,这可能是肾病HDL在清除过程中未能用apoE富集VLDL的结果。